论文部分内容阅读
目的评估湿润烧伤膏(MEBO)在促进慢性糖尿病足溃疡(DFUs)愈合中的疗效和安全性。方法 2005年至2010年间就诊于科威特艾哈迈迪医院的慢性糖尿病足溃疡患者被随机分为MEBO组(66例患者,82处溃疡)和生理盐水湿润敷料组(62例患者,78处溃疡)。前瞻性收集患者的人口统计学特征以及溃疡创面特点等数据。试验12周期间每隔两周计算一次患者的溃疡表面积(SA)和愈合指数(HI),24周时记录继发性截肢和新溃疡形成的情况。结果两组患者的人口学特征。临床症状及溃疡特点相似。MEBO组患者在第2周和第4周时分别有愈合指数的明显升高和溃疡表面积的明显下降(P<0.01);与生理盐水组在治疗12周时25.7%的完全愈合率相比,MEBO组一半以上的溃疡创面(53.7%)都实现了完全愈合(P=0.0006);治疗12周时,生理盐水组28.2%的患者愈合指数<0.5,而MEBO组无1例此状况(P=0.0001);治疗24周时,13位患者(10.2%)行足前段截肢术,而其中只有2例患者(3%)来自MEBO组(P=0.035);此外,每组各有2例患者在治疗24周后出现了新溃疡(P>0.05)。实验过程中MEBO组未见任何副反应。结论(1)除了具备安全性以外,MEBO可显著促进慢性糖尿病足溃疡的愈合,治疗12周时就可实现超过50%的完全愈合结果 ;2)MEBO组患者治疗24周后的截肢率也明显下降。
Objective To evaluate the efficacy and safety of MEBO in promoting the healing of chronic diabetic foot ulcers (DFUs). Methods Patients with chronic diabetic foot ulcer admitted to Kuwait’s Ahmadi Hospital from 2005 to 2010 were randomly divided into MEBO group (66 patients, 82 ulcers) and saline wet dressing group (62 patients, 78 ulcers) . Prospectively collect the patient’s demographic characteristics and characteristics of ulcer wounds and other data. Patient’s ulcer surface area (SA) and healing index (HI) were calculated every two weeks during the 12-week trial, and secondary amputation and neo-ulcer formation were recorded at 24 weeks. Demographic characteristics of the two groups of patients. Clinical symptoms and ulcer similar characteristics. MEBO group had significantly higher healing index and ulcer surface area at week 2 and week 4, respectively (P <0.01). Compared with 25.7% complete healing rate in saline group at 12 weeks, In the MEBO group, more than half of ulcer wounds (53.7%) were completely healed (P = 0.0006). At 12 weeks, 28.2% of patients in the saline group had a healing index of <0.5, while none in the MEBO group (P = 0.0001). At 24 weeks, 13 patients (10.2%) underwent anterior segment ankle surgery and only 2 of them (3%) were from the MEBO group (P = 0.035). In addition, 2 patients New ulcers occurred 24 weeks after treatment (P> 0.05). MEBO group during the experiment did not see any side effects. Conclusions (1) In addition to its safety, MEBO can significantly promote the healing of chronic diabetic foot ulcers, and over 50% complete healing results can be achieved after 12 weeks of treatment. 2) The amputation rate of MEBO group after 24 weeks of treatment is also obvious decline.